236 related articles for article (PubMed ID: 21328542)
1. ZNF703 gene amplification at 8p12 specifies luminal B breast cancer.
Sircoulomb F; Nicolas N; Ferrari A; Finetti P; Bekhouche I; Rousselet E; Lonigro A; Adélaïde J; Baudelet E; Esteyriès S; Wicinski J; Audebert S; Charafe-Jauffret E; Jacquemier J; Lopez M; Borg JP; Sotiriou C; Popovici C; Bertucci F; Birnbaum D; Chaffanet M; Ginestier C
EMBO Mol Med; 2011 Mar; 3(3):153-66. PubMed ID: 21328542
[TBL] [Abstract][Full Text] [Related]
2. High expression of ZNF703 independent of amplification indicates worse prognosis in patients with luminal B breast cancer.
Reynisdottir I; Arason A; Einarsdottir BO; Gunnarsson H; Staaf J; Vallon-Christersson J; Jonsson G; Ringnér M; Agnarsson BA; Olafsdottir K; Fagerholm R; Einarsdottir T; Johannesdottir G; Johannsson OT; Nevanlinna H; Borg A; Barkardottir RB
Cancer Med; 2013 Aug; 2(4):437-46. PubMed ID: 24156016
[TBL] [Abstract][Full Text] [Related]
3. ZNF703 gene copy number and protein expression in breast cancer; associations with proliferation, prognosis and luminal subtypes.
Klæstad E; Sawicka JE; Engstrøm MJ; Ytterhus B; Valla M; Bofin AM
Breast Cancer Res Treat; 2021 Feb; 186(1):65-77. PubMed ID: 33389351
[TBL] [Abstract][Full Text] [Related]
4. Who is in the driver's seat in 8p12 amplifications? ZNF703 in luminal B breast tumors.
Bazarov AV; Yaswen P
Breast Cancer Res; 2011 May; 13(3):308. PubMed ID: 21635707
[TBL] [Abstract][Full Text] [Related]
5. ZNF703 is a common Luminal B breast cancer oncogene that differentially regulates luminal and basal progenitors in human mammary epithelium.
Holland DG; Burleigh A; Git A; Goldgraben MA; Perez-Mancera PA; Chin SF; Hurtado A; Bruna A; Ali HR; Greenwood W; Dunning MJ; Samarajiwa S; Menon S; Rueda OM; Lynch AG; McKinney S; Ellis IO; Eaves CJ; Carroll JS; Curtis C; Aparicio S; Caldas C
EMBO Mol Med; 2011 Mar; 3(3):167-80. PubMed ID: 21337521
[TBL] [Abstract][Full Text] [Related]
6. Co-amplified genes at 8p12 and 11q13 in breast tumors cooperate with two major pathways in oncogenesis.
Kwek SS; Roy R; Zhou H; Climent J; Martinez-Climent JA; Fridlyand J; Albertson DG
Oncogene; 2009 Apr; 28(17):1892-903. PubMed ID: 19330026
[TBL] [Abstract][Full Text] [Related]
7.
Udu-Ituma S; Adélaïde J; Le TK; Omabe K; Finetti P; Paris C; Guille A; Bertucci F; Birnbaum D; Rocchi P; Chaffanet M
Pharmaceutics; 2023 Jul; 15(7):. PubMed ID: 37514116
[TBL] [Abstract][Full Text] [Related]
8. Integrated profiling of basal and luminal breast cancers.
Adélaïde J; Finetti P; Bekhouche I; Repellini L; Geneix J; Sircoulomb F; Charafe-Jauffret E; Cervera N; Desplans J; Parzy D; Schoenmakers E; Viens P; Jacquemier J; Birnbaum D; Bertucci F; Chaffanet M
Cancer Res; 2007 Dec; 67(24):11565-75. PubMed ID: 18089785
[TBL] [Abstract][Full Text] [Related]
9. ZNF703 is an important player in head and neck cancer.
Orhan C; Bakır B; Dalay N; Buyru N
Clin Otolaryngol; 2019 Nov; 44(6):1080-1086. PubMed ID: 31574205
[TBL] [Abstract][Full Text] [Related]
10. CCND1 Amplification in Breast Cancer -associations With Proliferation, Histopathological Grade, Molecular Subtype and Prognosis.
Valla M; Klæstad E; Ytterhus B; Bofin AM
J Mammary Gland Biol Neoplasia; 2022 Mar; 27(1):67-77. PubMed ID: 35459982
[TBL] [Abstract][Full Text] [Related]
11. ZNF703 promotes tumor cell proliferation and invasion and predicts poor prognosis in patients with colorectal cancer.
Ma F; Bi L; Yang G; Zhang M; Liu C; Zhao Y; Wang Y; Wang J; Bai Y; Zhang Y
Oncol Rep; 2014 Sep; 32(3):1071-7. PubMed ID: 25017610
[TBL] [Abstract][Full Text] [Related]
12. The long-term prognostic and predictive capacity of cyclin D1 gene amplification in 2305 breast tumours.
Lundberg A; Lindström LS; Li J; Harrell JC; Darai-Ramqvist E; Sifakis EG; Foukakis T; Perou CM; Czene K; Bergh J; Tobin NP
Breast Cancer Res; 2019 Feb; 21(1):34. PubMed ID: 30819233
[TBL] [Abstract][Full Text] [Related]
13. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.
Karlsson E; Waltersson MA; Bostner J; Pérez-Tenorio G; Olsson B; Hallbeck AL; Stål O
Genes Chromosomes Cancer; 2011 Oct; 50(10):775-87. PubMed ID: 21748818
[TBL] [Abstract][Full Text] [Related]
14. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer.
Cheang MC; Chia SK; Voduc D; Gao D; Leung S; Snider J; Watson M; Davies S; Bernard PS; Parker JS; Perou CM; Ellis MJ; Nielsen TO
J Natl Cancer Inst; 2009 May; 101(10):736-50. PubMed ID: 19436038
[TBL] [Abstract][Full Text] [Related]
15. ΔNp63α induces quiescence and downregulates the BRCA1 pathway in estrogen receptor-positive luminal breast cancer cell line MCF7 but not in other breast cancer cell lines.
Amin R; Morita-Fujimura Y; Tawarayama H; Semba K; Chiba N; Fukumoto M; Ikawa S
Mol Oncol; 2016 Apr; 10(4):575-93. PubMed ID: 26704768
[TBL] [Abstract][Full Text] [Related]
16. Loss of estrogen-regulated microRNA expression increases HER2 signaling and is prognostic of poor outcome in luminal breast cancer.
Bailey ST; Westerling T; Brown M
Cancer Res; 2015 Jan; 75(2):436-45. PubMed ID: 25388283
[TBL] [Abstract][Full Text] [Related]
17. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of amplification patterns and target genes at chromosome 11q13 in CCND1-amplified sporadic and familial breast tumours.
Holm K; Staaf J; Jönsson G; Vallon-Christersson J; Gunnarsson H; Arason A; Magnusson L; Barkardottir RB; Hegardt C; Ringnér M; Borg A
Breast Cancer Res Treat; 2012 Jun; 133(2):583-94. PubMed ID: 22002566
[TBL] [Abstract][Full Text] [Related]
19. Molecular analysis of hormone receptor positive (luminal) breast cancers: what have we learnt?
Loi S
Eur J Cancer; 2008 Dec; 44(18):2813-8. PubMed ID: 18990560
[TBL] [Abstract][Full Text] [Related]
20. Genomic Landscape and Endocrine-Resistant Subgroup in Estrogen Receptor-Positive, Progesterone Receptor-Negative, and HER2-Negative Breast Cancer.
Liu XY; Ma D; Xu XE; Jin X; Yu KD; Jiang YZ; Shao ZM
Theranostics; 2018; 8(22):6386-6399. PubMed ID: 30613307
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
